Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-12-12, Stock:NVS, The news for the past five days is as follows:
2019-12-05: NEWS1: Novartis (NVS) Gains But Lags Market: What You Should Know.NEWS2: Astellas-Audentes Deal Likely to Ignite More Acquisitions.NEWS3: U.S. FDA approves generic versions of Novartis blockbuster MS treatment.NEWS4: Companies Are Merging Like Mad. That Might Signal a Looming Economic Slowdown..NEWS5: UPDATE 1-Novartis R&D boss says doesn't see big opportunity in oral SMA therapy.NEWS6: The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission.NEWS7: Is Novartis AG  (NVS) A Good Stock To Buy?.
2019-12-06: NEWS1: Are more good times ahead for M&A?.NEWS2: Biogen Up on New Data on Alzheimer's Candidate Aducanumab.NEWS3: Regeneron Reports Positive Data on Rare Blood Disorder Drug.NEWS4: Is Biogen Stock A Buy After Rocketing On A New Analysis In Alzheimer's?.NEWS5: The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend.NEWS6: Swiss approve insurance cover for Novartis, Gilead cell therapies.
2019-12-09: NEWS1: Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting.NEWS2: Gilead (GILD) Announces Positive Long-Term Data on Yescarta.
2019-12-10: NEWS1: Why Biotech ETFs are Surging to New Highs.NEWS2: China’s Curing Cancer Faster and Cheaper Than Anywhere Else.NEWS3: Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research.NEWS4: StockBeat: Sanofi Surges After Ditching Diabetes, Cardio Research.
2019-12-11: NEWS1: Top Research Reports for Novartis, AbbVie & Sanofi.NEWS2: Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDA.NEWS3: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint.

Answer: Rise